Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Receptor BioLogix Inc., based in South San Francisco, Calif., was founded in July 2003 with initial seed capital and an exclusive technology license from Oregon Health Sciences University. The company is focused on developing the first broad-spectrum anti-HER therapeutic, resulting from its program to commercialize a newly discovered class of protein therapeutics called Intron Fusion ProteinsÔ (IFPÔ) to treat cancer, autoimmune, metabolic and other diseases. Receptor BioLogix has identified a protein that blocks intracellular signaling triggered by members of the epidermal growth factor (EGF) receptor family, including the HER-2 receptor that is abnormally expressed in some 30 percent of breast cancer ( www.receptorbiologix.com )
Receptor BioLogix , Inc.
1140 Veterans Blvd. Suite A
South San Francisco, California 94080
USA
Tel: (650) 266-4613